Improve the Service, Double the Retained Profit, Medify Solutions Limited Announces

Toronto (ots/PRNewswire) - Medify Solutions Limited today
announces its own in-house product for roll out to the NHS.

This new capability will replace the legacy generic solution
provided for Medify by Pervasic and specifically focuses on the known
requirements of Healthcare professionals and the global delivery of
MedifyRemote.

The development has been led by the company's NHS team working
with Medify's live projects to deliver and meet the needs and
expectations of Medify's healthcare clients and the patient.

This investment has been planned by the board of Medify to ensure
total and complete ownership of not only the customer proposition,
but also the complete IPR for all Medify applications. Furthermore,
it will significantly contribute to Medify's ability to fulfil its
service provider status for clients globally, enabling the core
delivery of contractual services to be managed in house by Medify
immediately removing third party costs.

Jonathan Bryant, Executive Chairman, said: "This development has
been completed ahead of schedule and I am delighted, as are our
customers, with the new MedifyRemote application approach. Not only
does this provide product and corporate ownership to the company and
its shareholders, but in a single move increases our revenue and
profit margins two fold. Long-term objectives been achieved and short
term commercial rewards have been exceeded. The team, led by new
Group CEO Ian O'Reilly, will accelerate a more commercially
profitable era for the company and the move into a total solutions
and service provider status with our governmental and corporate
clients."

This news release contains forward-looking statements that are
subject to certain risks and uncertainties that may cause actual
results to differ materially from those projected on the basis of
such forward-looking statements. The words "estimate," "project,"
"intends," "expects," "believes," and similar expressions are
intended to identify forward-looking statements. Such forward-looking
statements are made based on management's beliefs, as well as
assumptions made by, and information currently available to,
management pursuant to the "safe-harbour" provisions of the Private
Securities Litigation Reform Act of 1995. For a more complete
description of these and other risk factors that may affect the
future performance of Medify Solutions Limited, see "Risk Factors" in
the Company's Annual Report on Form 10-KSB and its other filings with
the Securities and Exchange Commission. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date made and the Company undertakes no obligation to
disclose any revision to these forward-looking statements to reflect
events or circumstances after the date made or to reflect the
occurrence of unanticipated events.

ots Originaltext: Medify Solutions Limited
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information: Medify Press Office:
press@medifysolutions.com